Generic · Injection
Fluphenazine 2.5 mg/mL injection price what pharmacies pay, and what you should
There is no weekly pharmacy acquisition cost for fluphenazine 2.5 mg/ml injection this week. The makers, package codes, recalls and label are below.
What people paid for fluphenazine 2.5 mg/ml injection
What did your pharmacy charge? It takes 30 seconds, it's anonymous - and it shows everyone which pharmacies are fair.
Supply status: shortages & recalls
Recalls
Showing the 6 most relevant of 14 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
Every manufacturer and package code
1 company sell fluphenazine 2.5 mg/ml injection under 1 package code (NDC).
| Maker | Package codes | Per unit |
|---|---|---|
| Fresenius Kabi USA, LLC | 63323-281-10 | - |
All 1 package codes
A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.
Other fluphenazine strengths and forms
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 25 mg/mL injection | $10.46 | $52.29 / 5 mL | ||
| 0.5 mg/mL oral solution | Not priced this week | |||
| 5 mg/mL oral solution | Not priced this week | |||
| 1 mg tablet | $0.2371 | $7.11 / 30 tablets | ||
| 2.5 mg tablet | $0.2476 | $7.43 / 30 tablets | ||
| 5 mg tablet | $0.2363 | $7.09 / 30 tablets | ||
| 10 mg tablet | $0.3898 | $11.69 / 30 tablets | ||
Official label & what changed
Fluphenazine Hydrochloride Tablets, USP
WARNING
Increased Mortality in Elderly Patients with Dementia-Related Psychosis:
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Fluphenazine hydrochloride is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Questions about fluphenazine 2.5 mg/ml injection
Who makes fluphenazine 2.5 mg/ml injection?
1 company: Fresenius Kabi USA, LLC. See every package code.
Is fluphenazine in shortage?
No shortage is reported right now. We check every day.
Has fluphenazine been recalled?
14 recalls on record, 10 ongoing. Recalls name specific lots - check yours.
What does "pharmacies pay" mean?
It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.
Talk about fluphenazine 2.5 mg/ml injection
No comments yet. Questions, tips, what worked for you - start the conversation.